GeneDx Reports Q3 2026 Revenue of $123.1 Million, Adjusted EPS of $0.28
Third-quarter revenue slightly exceeded FactSet’s $122.9 million estimate, while adjusted EPS of $0.28 topped the $0.07 estimate. GeneDx expects fourth-quarter revenue of $135.0 million and reiterated full-year revenue guidance of $475 million to $490 million.
GeneDx Holdings Corp. reported third-quarter 2026 revenue of $123.1 million, slightly exceeding the FactSet consensus estimate of $122.9 million. The company also posted an adjusted earnings per share of $0.28, significantly outperforming the FactSet estimate of $0.07. Looking ahead, the company provided a revenue expectation of $135.0 million for the fourth quarter of 2026.
Additionally, GeneDx reiterated its full-year 2026 revenue guidance in the range of $475 million to $490 million, compared to the FactSet estimate of $482.3 million.